Antiarrhythmic drug, cibenzoline, can directly improve the left ventricular diastolic function in patients with hypertrophic cardiomyopathy

Japanese Circulation Journal

Volumn 65, Issue 6, 2001, Pages 531-538

  Hamada, M ^a   Shigematsu, Y ^a   Hara, Y ^a   Suzuki, M ^a   Ohtsuka, T ^a   Hiasa, G ^a   Ogimoto, A ^a   Saeki, H ^a   Suzuki, J ^a   Hiwada, K ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium channels; Cibenzoline; Hypertrophic cardiomyopathy; Left ventricular diastolic function; Left ventricular systolic function

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; CIBENZOLINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE PRESSURE; HEART SOUND; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; MALE; MECHANOCARDIOGRAPHY; SCINTIANGIOGRAPHY;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; BLOOD PRESSURE; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GATED BLOOD-POOL IMAGING; HEART FUNCTION TESTS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; VENTRICULAR FUNCTION, LEFT;

EID: 0035018937     PISSN: 00471828     EISSN: None     Source Type: Journal    
DOI: 10.1253/jcj.65.531     Document Type: Article

References (37)

1. Treatment of hypertrophic obstructive cardiomyopathy with verapamil
2. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects
3. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status
4. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole
5. 2+ inward current by the class I antiarrhythmic agent, cibenzoline
6. 2+ channel inhibitory effects of cibenzoline with verapamil on guinea-pig heart
7. Class Ia antiarrhythmic drug cibenzoline. A new approach to the medical treatment of hypertrophic obstructive cardiomyopathy
8. An early systolic sound associated with midventricular obstruction in a patient with hypertrophic cardiomyopathy
9. A case of hypertrophic cardiomyopathy with mid-ventricular obstruction with splenic infarction associated with paroxysmal atrial fibrillation
10. Report of the 1995 World Health Organization/International Society and Federation of Cardiology. Task force on the definition and classification of cardiomyopathies
11. Doppler echocardiographic determination of the pressure gradient in hypertrophic cardiomyopathy
12. Age and cibenzoline disposition
13. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements
14. Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension
15. Clinical significance of systolic time intervals for the evaluation of left ventricular function in patients with coronary artery disease
16. Clinical significance of systolic time intervals in hypertensive patients
17. Bedside technics for the evaluation of ventricular function in man
18. Diagnostic significance of early diastolic time intervals in patients with hypertrophic cardiomyopathy and myocardial hypertrophy due to essential hypertension
19. Hypertrophic obstructive cardiomyopathy: Initial results and long-term follow-up after Morrow septal myectomy
20. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy
21. Impact of dualchamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy
22. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients
23. Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: Studies to develop a new catheter-based concept of treatment
24. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): Catheter interventional treatment for hypertrophic obstructive cardiomyopathy
25. Effects on rabbit nodal, atrial, ventricular and purkinje cell potentials of a new antiarrhythmic drug, cibenzoline, which protects against action potential shortening in hypoxia
26. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy
27. The cardiac effects of d- and 1-disopyramide in normal subjects: A noninvasive study
28. Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressures in patients with cardiomyopathies: A simultaneous Doppler echocardiographic and cardiac catheterization study
29. Comparative effects of calcium-channel blockers and beta-adrenergic blocker on early diastolic time intervals and A-wave ratio in patients with hypertrophic cardiomyopathy
30. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy
31. Induced septal infarction. A new therapeutic strategy for hypertrophic obstructive cardiomyopathy
32. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy
33. Effects of verapamil on left ventricular systolic and diastolic function in patients with hypertrophic cardiomyopathy: Pressure-volume analysis with a nonimaging scintillation probe
34. Altered mitral flow pattern in patients with hypertrophic obstructive cardiomyopathy: Response
35. Effect of disopyramide on systolic and early diastolic time intervals in patients with hypertrophic cardiomyopathy
36. Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy: Comparison with diltiazem
37. Comparison of anticholinergic effects of cibenzoline, disopyramide, and atropine